Benzinga has provided a thorough analysis of PaxMedia (PXMD) This is definitely nanocap territory. The capital raise is roughly $8.5million. That meets the definition of nanocap for a clinical stage biotech. https://www.benzinga.com/money/is-paxmedica-inc-ipo-a-good-buy
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.